# EDGAR Filing Document

**Accession Number:** 0001557376
**File Stem:** 0001829126-26-003684
**Filing Date:** 2026-4
**Character Count:** 10505
**Document Hash:** 720399de8f5e6d51bea2c868d2867f55
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001829126-26-003684.hdr.sgml**: 20260421

**ACCESSION NUMBER**: 0001829126-26-003684

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20260421

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260421

**DATE AS OF CHANGE**: 20260421

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Zeo ScientifiX, Inc.
- **CENTRAL INDEX KEY:** 0001557376
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 474180540
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1031

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-55008
- **FILM NUMBER:** 26876721

**BUSINESS ADDRESS:**
- **STREET 1:** 3321 COLLEGE AVENUE
- **STREET 2:** SUITE 246
- **CITY:** DAVIE
- **STATE:** FL
- **ZIP:** 33314
- **BUSINESS PHONE:** 888-963-7881

**MAIL ADDRESS:**
- **STREET 1:** 3321 COLLEGE AVENUE
- **STREET 2:** SUITE 246
- **CITY:** DAVIE
- **STATE:** FL
- **ZIP:** 33314

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Organicell Regenerative Medicine, Inc.
- **DATE OF NAME CHANGE:** 20180625

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Biotech Products Services & Research, Inc.
- **DATE OF NAME CHANGE:** 20150917

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** BESPOKE TRICYCLES INC
- **DATE OF NAME CHANGE:** 20120831

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

**Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934**

Date of report (Date of earliest event reported): **April 21, 2026**

**<u>ZEO SCIENTIFIX, INC.</u>**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Nevada** | **000-55008** | **47-4180540** |
| (State or Other Jurisdiction<br>of Incorporation) | (Commission<br>File Number) | (IRS Employer<br>Identification No.) |

---

---

| | |
|:---|:---|
| **3321 College Avenue, Suite 246<br> Davie, Florida** | **33314** |
| (Address of Principal Executive Offices) | (Zip Code) |

---

Registrant's telephone number, including area code: **<u>(888) 963-7881</u>**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each Class** | **Trading Symbol** | **Name of each exchange on which registered** |
| None | N/A | N/A |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

As used in this Current Report on Form 8-K (this "**Report**"), and unless otherwise indicated, the terms "**the Company**," "**ZEO**," "**we**," "**us**" and "**our**" refer to Zeo ScientifiX, Inc.

**Item 8.01 Other Events.**

On April 21, 2026, ZEO issued a press release announcing it had achieved a significant milestone by successful training over 500 clinicians through its monthly Masterclass series in regenerative biologics treatments.

A copy of the press release is included as **Exhibit 99.1** to this Report.

**Item 9.01 Financial Statements and Exhibits.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) *Exhibits* 

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 99.1 | [Press Release, dated April 21, 2026](zeoscientifix_ex99-1.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Dated: April 21, 2026 | **ZEO SCIENTIFIX, INC.** | **ZEO SCIENTIFIX, INC.** |
|  | By: | /s/ Ian T. Bothwell |
|  |  | Ian T. Bothwell<br> Chief Executive Officer and Chief Financial Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

**FOR IMMEDIATE RELEASE: APRIL 21, 2026**

**ZEO ScientifiX Surpasses 500 Physicians Trained in Regenerative Medicine Compliance; Monthly Masterclasses Average 70+ Clinicians**

**DAVIE, FL —** ZEO ScientifiX, Inc. (OTCQB: ZEOX) ("ZEO ScientifiX"), a provider of industry-leading clinical education in regenerative medicine innovation, proudly announces a significant milestone: the successful training of over 500 clinicians through its monthly Masterclass series. ZEO believes that its educational program, held at Nova Southeastern University's Center of Innovation in Davie, has become a vital resource for physicians nationally navigating the evolving regulatory and scientific landscape of treatment with regenerative biologics, including stem cells and extracellular vesicles (EVs).

The ZEO Masterclass is a rigorous, one-day intensive designed for clinical decision-makers. Since its inception, the program has maintained a consistent and significant reach, notably hosting over 70 attendees every month. The curriculum provides a deep dive into Florida's specific regulatory requirements, evidence-based science, and the operational frameworks necessary for responsible clinical integration.

**Market Demand and Operational Integrity**

As the regenerative medicine field faces increased scrutiny, ZEO ScientifiX has prioritized an "education beats promotion" philosophy. The program addresses the narrowing margin for error in the industry by providing direct access to healthcare attorneys, Ph.D. researchers, and veteran clinicians.

"Surpassing the 500-physician mark is a testament to the sheer demand for high-level, compliant education in this space," said Sean Vega-Stanton, M.S., General Manager of Operations at ZEO ScientifiX. "Every session has reached capacity, which confirms that physicians are moving beyond curiosity and are now committed to understanding how to bring these biologics into their practices the right way. At ZEO ScientifiX, we believe our leadership must extend beyond manufacturing quality to include the empowerment of the physicians using our products."

**Establishing a New Standard of Care**

The impact of this training extends beyond the classroom and directly into the clinical setting, where standardized protocols are becoming the benchmark for success.

"Training more than 500 physicians in regenerative biologics represents a defining moment for the field," said George C. Shapiro, M.D., FACC, Chief Medical Officer of ZEO ScientifiX. "By equipping clinicians with the latest evidence-based frameworks in exosome therapeutics and precision longevity medicine, ZEO ScientifiX is not simply advancing professional education—it is seeking to fundamentally raise the standard of care available to patients across the country."

**Comprehensive Curriculum and Expert Faculty**

A cornerstone of the ZEO Masterclass series is the rotation of monthly expert keynote speakers, ensuring that attendees receive the most current perspectives on clinical application and research. Notable past and recurring experts include leaders such as **Dr. David Karli** and **Dr. Faryal Farooqui**, who provide specialized insights into the practical use of regenerative therapies.

The core Masterclass faculty includes:

● Sean Vega-Stanton, M.S. (General Manager of Operations)

● Edgar J. Aseby, Esq. (Healthcare Attorney, Regulatory & Compliance)

● Michael Bellio, Ph.D. (VP of Research & Manufacturing)

● George Shapiro, M.D., FACC (Chief Medical Officer)

● Karlista Maroney (Director of Growth Strategy)

● Tami Banno (Director of Practice Development)

● Bob Smoley (Board Advisor)

Attendees participate in sessions covering ethical sourcing, manufacturing quality, risk mitigation, and turn-key practice solutions, concluding with a tour of the ZEO ScientifiX research and lab facilities.

**Upcoming Opportunities**

ZEO ScientifiX continues its commitment to physician excellence with the next Masterclass scheduled for April 24 at Nova Southeastern University's Center of Innovation. Registration is limited to clinicians and practice owners to ensure an environment focused on clinical and operational integrity.

**About ZEO ScientifiX, Inc.**

ZEO ScientifiX, Inc. (OTCQB: ZEOX) is an SEC-reporting, clinical-stage biopharmaceutical company focused on the research, development, and manufacturing of regenerative biologics. Operating out of Nova Southeastern University's Center of Collaborative Research, the Company translates emerging science into scalable clinical solutions. For more information, visit https://zeoscientifix.com.

**Forward-Looking Statements**

Certain statements contained in this press release should be considered forward-looking statements within the meaning of the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. Actual results could vary dramatically. ZEO has no intention and specifically disclaims any duty to update the information in this press release.

**Media Contact:**

Karlista Maroney

ZEO ScientifiX, Inc.

Karlista@zeoscientifix.com